Striking study results last year indicated a new type of medicine may improve on Merck’s dominant immunotherapy, spurring a ...
A recent CNN report cast a spotlight on Akeso, a Chinese biotech company whose immunotherapy ivonescimab drug, now in ...
We recently published a list of 25 Best Dividend Stocks to Buy According to Billionaires. In this article, we are going to ...
A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney ...
AstraZeneca and Daiichi Sankyo's Enhertu has become the first HER2-directed drug to mount a patient survival benefit in a ...
Zacks.com on MSN3h
CytomX Gears Up to Report Q4 Earnings: What Should Investors Expect?CytomX Therapeutics CTMX, a clinical-stage oncology company, is slated to report its fourth-quarter 2024 earnings results on ...
The PD-1 Inhibitor Drugs Market is expanding due to the rising prevalence of cancer and autoimmune diseases. PD-1 inhibitors, including pembrolizumab, nivolumab, and cemiplimab, play a crucial role in ...
Patients with PD-L1-positive tumors lived more than seven months longer on Tevimbra added to chemotherapy compared to just chemo.
The Jha brothers are accused of trafficking in various falsified medicines, including knock-offs of Merck & Co's Keytruda.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback